Switch theme
Sign up to access all valuation multiples
Originally spun out of Bristol-Myers Squibb, ConvaTec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
2016
10.5K+
LTM Revenue $1.8B
LTM EBITDA $466M
$9.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ConvaTec Group has a last 12-month revenue (LTM) of $1.8B and a last 12-month EBITDA of $466M.
In the most recent fiscal year, ConvaTec Group achieved revenue of $3.1B and an EBITDA of $725M.
ConvaTec Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ConvaTec Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8B | XXX | $3.1B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | $466M | XXX | $725M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $388M | XXX | $445M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $253M | XXX | $256M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ConvaTec Group's stock price is GBP 3 (or $4).
ConvaTec Group has current market cap of GBP 5.9B (or $8.0B), and EV of GBP 6.8B (or $9.1B).
See ConvaTec Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.1B | $8.0B | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ConvaTec Group has market cap of $8.0B and EV of $9.1B.
ConvaTec Group's trades at 3.0x EV/Revenue multiple, and 12.6x EV/EBITDA.
Equity research analysts estimate ConvaTec Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ConvaTec Group has a P/E ratio of 23.4x.
See valuation multiples for ConvaTec Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.0B | XXX | $8.0B | XXX | XXX | XXX |
| EV (current) | $9.1B | XXX | $9.1B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 14.5x | XXX | 12.6x | XXX | XXX | XXX |
| EV/EBIT | 17.5x | XXX | 20.5x | XXX | XXX | XXX |
| EV/Gross Profit | 6.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.4x | XXX | 31.2x | XXX | XXX | XXX |
| EV/FCF | 27.2x | XXX | 24.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialConvaTec Group's last 12 month revenue growth is 2%
ConvaTec Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
ConvaTec Group's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ConvaTec Group's rule of X is 30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ConvaTec Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | -9% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ConvaTec Group acquired XXX companies to date.
Last acquisition by ConvaTec Group was XXXXXXXX, XXXXX XXXXX XXXXXX . ConvaTec Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ConvaTec Group founded? | ConvaTec Group was founded in 2016. |
| Where is ConvaTec Group headquartered? | ConvaTec Group is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does ConvaTec Group have? | As of today, ConvaTec Group has 10.5K+ employees. |
| Who is the CEO of ConvaTec Group? | ConvaTec Group's CEO is Mr. Karim Bitar. |
| Is ConvaTec Group publicy listed? | Yes, ConvaTec Group is a public company listed on LON. |
| What is the stock symbol of ConvaTec Group? | ConvaTec Group trades under CTEC ticker. |
| When did ConvaTec Group go public? | ConvaTec Group went public in 2016. |
| Who are competitors of ConvaTec Group? | Similar companies to ConvaTec Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of ConvaTec Group? | ConvaTec Group's current market cap is $8.0B |
| What is the current revenue of ConvaTec Group? | ConvaTec Group's last 12 months revenue is $1.8B. |
| What is the current revenue growth of ConvaTec Group? | ConvaTec Group revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of ConvaTec Group? | Current revenue multiple of ConvaTec Group is 3.8x. |
| Is ConvaTec Group profitable? | Yes, ConvaTec Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ConvaTec Group? | ConvaTec Group's last 12 months EBITDA is $466M. |
| What is ConvaTec Group's EBITDA margin? | ConvaTec Group's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of ConvaTec Group? | Current EBITDA multiple of ConvaTec Group is 14.5x. |
| What is the current FCF of ConvaTec Group? | ConvaTec Group's last 12 months FCF is $250M. |
| What is ConvaTec Group's FCF margin? | ConvaTec Group's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of ConvaTec Group? | Current FCF multiple of ConvaTec Group is 27.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
